Tuesday, 04 Nov 2025

MedPulse360

Sign In

Medical Research

STAT+: Alnylam could be the next mega-cap biotech

Written by

Published

September 13, 2025

0 min

Might Alnylam be the next mega-cap biotech? It has momentum.

Tags:

Previous Article

Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy

Next Article

Government to limit high-risk cosmetic procedures to be carried out by doctors only

📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago